So Part D is still central to the Bridge as an eligibility requirement, even though the plan-based BALANCE coverage is not happening for now
Usually only one eye is affected
Pratley RE, Aroda VR, Lingvay I, Ldemann J, Andreassen C, Navarria A et al (2018) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Safety, tolerability, muscle preservation, medical history, and long-term maintenance matter
Its also essential to discuss potential side effects and how to recognize serious symptoms, such as allergic reactions, severe abdominal pain, or low blood sugar, especially if you have diabetes or take related medications
Semaglutide can cause skin sensitivity in some users, though it is not the most common side effect